Form 4: Vaccinex Director Bala S. Manian Acquires Options in Lieu of Cash Compensation
SEC Form 4
Director Bala S. Manian acquired options to purchase Vaccinex, Inc. common stock in lieu of cash compensation and as part of the company's 2018 Omnibus Incentive Plan.
Summary
- Bala S. Manian, a director of Vaccinex, Inc., reported changes in beneficial ownership on May 14, 2024.
- The report details the acquisition of stock options on May 10, 2024.
- Manian acquired 2,685 stock options with an exercise price of $5.75, receiving them in lieu of $10,625 for retainer and meeting fees during the first quarter of 2024.
- These options were calculated using the Black-Scholes valuation model and are immediately exercisable.
- Additionally, Manian acquired 10,108 stock options with an exercise price of $5.75, granted under the company's 2018 Omnibus Incentive Plan.
- These options expire on May 10, 2034, or five years following retirement or cessation of services.
- The filing also reflects the Issuer's 1-for-15 reverse stock split effected on September 25, 2023 and 1-for-14 reverse stock split effected on February 19, 2024.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine filing indicating standard compensation practices. The director's acquisition of options could be seen as a mildly positive signal.
Positives
- The acquisition of options by a director can be seen as a positive sign, indicating confidence in the company's future performance.
- The use of options in lieu of cash compensation can conserve the company's cash reserves.
Future Outlook
The document does not contain specific forward-looking statements beyond the expiration dates of the granted options.
Industry Context
Director compensation through stock options is a common practice in the biotechnology industry, aligning management's interests with those of shareholders. This encourages long-term value creation.
Comparison to Industry Standards
- Granting stock options to directors is a common practice among biotech companies, such as Amgen, Gilead Sciences, and Biogen, to align their interests with shareholders.
- The Black-Scholes model is a standard valuation method for stock options, ensuring fair compensation.
- Director compensation packages vary widely, but the use of options in lieu of cash is often seen in companies looking to conserve capital.
Related Party Transactions
- The grant of stock options to Bala S. Manian, a director, is a related party transaction that is disclosed in the filing.
Stakeholder Impact
- The granting of stock options to a director can align the director's interests with those of the shareholders, potentially leading to increased shareholder value.
- The use of options in lieu of cash compensation can help the company conserve cash, which could benefit creditors and other stakeholders.
Key Dates
| Date | Description |
|---|---|
| 05/15/2020 | Date of stock option grant with an expiration date of May 14, 2029. |
| 05/14/2021 | Date of stock option grant with an expiration date of May 12, 2030. |
| 05/11/2022 | Date of stock option grant with an expiration date of May 9, 2031. |
| 05/12/2023 | Date of stock option grant with an expiration date of May 9, 2032. |
| 09/25/2023 | Vaccinex effected a 1-for-15 reverse stock split. |
| 02/19/2024 | Vaccinex effected a 1-for-14 reverse stock split. |
| 05/10/2024 | Date of the reported transaction: acquisition of stock options. |
| 05/11/2024 | Date of stock option grant with an expiration date of May 8, 2033. |
| 05/14/2024 | Date of Form 4 filing. |
| 05/10/2034 | Expiration date of options granted under the 2018 Omnibus Incentive Plan. |
Keywords
Vaccinex, Director, Stock Options, Beneficial Ownership, Form 4, Compensation, Reverse Stock Split
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.